There are 2 papers on amyloid β1−40 in aging research: 1 trial and 1 observational study in people.
2 papers study it3 findings
See all 2 papers on amyloid β1−40
“and in Aβ1-40 (-52.1, -40.3, and -50.7% vs. -30.7%, P < 0.05).”
- Human trial1
- Humans1
Associations
3Liraglutide + empagliflozin
downin humans1
1 study
Liraglutide + empagliflozin
downin humans1
Liraglutide + empagliflozin is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-50.7% versus -30.7% with insulin).
HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183
Empagliflozin
downin humans1
1 study
Empagliflozin
downin humans1
Empagliflozin is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-40.3% versus -30.7% with insulin).
HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183
Liraglutide
downin humans1
1 study
Liraglutide
downin humans1
Liraglutide is associated with amyloid β1−40 in humans (Metformin-treated type 2 diabetes; compared with insulin) (-52.1% versus -30.7% with insulin).
HumansMetformin-treated type 2 diabetes; compared with insulinplasma12 monthsn = 183